RenovoRx (RNXT) Accumulated Depreciation (2025)

RenovoRx's (RNXT) quarterly Accumulated Depreciation came in at $2000.0 in Q4 2025, little changed quarter-over-quarter from $2000.0 in Q3 2025.

Analysis

RenovoRx (RNXT) Accumulated Depreciation (2025) Analysis & Trends

RenovoRx has disclosed Accumulated Depreciation across 1 years of filings, most recently posting $2000.0 for Q4 2025.

In Q4 2025, Accumulated Depreciation changed N/A year-over-year to $2000.0; the TTM figure through Dec 2025 stood at $2000.0 (changed N/A YoY), while the FY2025 annual figure was $2000.0, changed N/A from the prior year.
Accumulated Depreciation came in at $2000.0 for Q4 2025 at RenovoRx, roughly flat from $2000.0 in the prior quarter.
In the past five years, Accumulated Depreciation ranged from a high of $2000.0 in Q2 2025 to a low of $1000.0 in Q1 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	179.79 Bn	174.18 Bn	7.27 Bn
2	Intuitive Surgical	127.69 Bn	122.47 Bn	1.96 Bn
3	Medtronic	117.23 Bn	108.41 Bn	6.34 Bn
4	Stryker	103.55 Bn	100.07 Bn	4.50 Bn
5	Boston Scientific	63.24 Bn	62.70 Bn	3.85 Bn
6	Edwards Lifesciences	49.97 Bn	45.72 Bn	1.35 Bn
7	Alcon	32.83 Bn	31.37 Bn	1.68 Bn
8	Dexcom	32.30 Bn	30.35 Bn	830.00 Mn
9	Steris	20.73 Bn	20.25 Bn	684.20 Mn
10	RenovoRx	83.48 Mn	83.48 Mn	766,000.00

Historic Data

Download Data